To assess the effect of chlorhexidine gluconate and benzydamine hydrochloride mouth spray, used in conjunction with antibiotic treatment, on the intensity of clinical signs and quality of life of patients with group A streptococcal tonsillopharyngitis.

Patients (n = 147) with streptococcal tonsillopharyngitis were recruited and randomly allocated to either the treatment group (penicillin plus chlorhexidine and benzydamine; n = 72) or control group (penicillin plus placebo; n = 75). Blinded assessments were conducted before and after 10 days' treatment, using an intensity rating scale for clinical sign severity, a visual analogue scale for subjective health state, the Short Form 36 Health Questionnaire for quality of life, and a customised questionnaire for side effects.

The treatment group showed a statistically significant reduction in the intensity of clinical signs, compared with the control group. On treatment day 7, there was no significant difference in quality of life between the treatment and control groups. The treatment drugs were well tolerated, and no serious adverse events were observed.

Chlorhexidine gluconate and benzydamine hydrochloride mouth spray, added to standard antibiotic treatment, significantly alleviate the intensity of clinical signs in patients with streptococcal pharyngitis. Further research is needed using larger sample sizes or alternative control groups.

The use of nasal creams and ointments in the conservative management of anterior epistaxis is well documented and supported. This study set out to obtain a national opinion, in order to establish current practice.

A survey of all Scotland-based otolaryngology clinicians was conducted. Participants were asked which topical treatment they used in their practice, how often and for how long they advocated its use, and how they advised their patients to apply it.

The overall response rate was 91 per cent. We discuss and compare the varying responses for the questions posed, and discuss the possible reasons for these in greater detail.

This study demonstrates a high degree of variation in this practice, arising from a lack of concrete evidence and influenced by anecdotal experience and personal preferences. Definitive comparative studies are required if a ‘gold standard’ topical approach for the management of anterior epistaxis is to emerge.

The aim of this study was to determine how aware ENT practitioners are that Naseptin® (Alliance), widely used in ENT practice, contains peanut oil and to what extent this is conveyed to patients.

A questionnaire was sent out to all ENT practitioners registered with the British Association of Otolaryngologists.

Analysis of the data confirmed that Naseptin cream is widely used in ENT practice and showed that although most practitioners are aware that Naseptin cream contains refined peanut oil (arachis oil) (74.3 per cent of consultants and 93.6 per cent of registrars) not all ask their patients whether they are allergic to peanuts (62.6 per cent of consultants and 87.3 per cent of registrars).

The results suggest that more should be done to raise awareness amongst practitioners that Naseptin cream contains peanut oil and should be avoided in patients with a peanut allergy, as recommended by national guidelines. The use of Naseptin cream when contraindicated may have medicolegal implications.